RESOURCE / PUBLIC SOURCE RECORD
Trade Mission: Advancing Norwegian radiopharma and precision oncology in Japan
- Delegation/trade mission ran 23–27 June 2025 in Japan; programme locations include Tokyo and Osaka. Organiser: Innovation Norway. Partners: Business Sweden; Denmark, Finland and Iceland’s embassies; Legemiddelindustrien; Nordic Innovation House Tokyo; and Oslo Cancer Cluster. No fee or registration details shown.
- Participating companies named or linked: GE Healthcare, Bayer Norway, Agiler Pharma AS, Norsk Medisinsk Syklotronsenter AS, Oncoinvent ASA and a company linked as augere.md (company name not displayed in the accessible text). The mission aimed to present Norwegian capability in radiopharmaceuticals and precision oncology as a country team and connect with Japanese pharmaceutical companies, investors and healthcare stakeholders during Osaka Expo 2025 Health Week. Highlights included meetings with pharma and investors at the 4th Nordic Health Summit Japan, a Norway–Japan radiopharma/oncology roundtable, Nordic Health EXPO at Osaka Expo, B2B meetings, health-authority discussions and site visits to Japanese biopharma companies.
- The page characterised Japan as the world’s third-largest healthcare market, citing 125 million people, 4% annual growth for 2018–2024, leading pharmaceutical companies Takeda, Astellas and Eisai, universal health coverage, and healthcare spending of 11% of GDP.
- Contacts: Michal Louis Berg, Senior Market Advisor / Investment Manager, Tokyo (michal.louis.berg@innovationnorway.no; +818 050210656; LinkedIn: linkedin.com/in/michal-louis-berg-02827088/); Marianne Støren Berg, Counsellor for Science, Technology and Higher Education, Japan (email shown as marianne.storen.berg@innovationnnorway.no; +47 926 03 665). The page linked related GE Healthcare and Norwegian biopharma material, the Nordic Health Summit Japan 2025 event, and Expo partner packages. Responsible-business/ESG and due-diligence conditions applied.